High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019

339Citations
Citations of this article
488Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.

Cite

CITATION STYLE

APA

Cao, W., Liu, X., Bai, T., Fan, H., Hong, K., Song, H., … Li, T. (2020). High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infectious Diseases, 7(3), 1–6. https://doi.org/10.1093/ofid/ofaa102

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free